Ecolab Delivers on Commitments to Save Water in Historic AI Era
21.3.2025 12:00:00 CET | Business Wire | Press Release
Water is the world’s most essential resource, and it’s only grown more critical in the age of AI. During this transformative digital revolution, Ecolab, a global sustainability leader that maximizes growth and performance through water solutions and infection prevention services, has continued to meet its goals and work with customers to deliver profitability while advancing optimized water use.
By 2030, it is estimated that AI-related growth will demand additional power equivalent to the annual needs of India1 and as much water to meet the annual drinking water needs of the United States2. As the world navigates the growth of AI and high-tech data centers, there is a unique opportunity to leverage AI to help drive efficiency and innovation in circular water management to improve operational processes and conserve natural resources. Ecolab’s mission to help protect water while driving business growth is more important than ever.
“The rapid acceleration of AI technology is increasing demands on our water and energy resources, yet it also offers unprecedented opportunity to address the water crisis through proprietary connected systems and powerful insights,” said Christophe Beck, chairman and CEO of Ecolab. “By leveraging AI to reduce, reuse and repurpose water throughout business operations, we can continue to win the right way by delivering positive performance for customers while protecting natural resources.”
Ecolab, together with its customers, made significant progress in 2024 to advance water stewardship and help build a more resilient and profitable future. This World Water Day, Ecolab celebrates these achievements in protecting water resources while continuing to grow. Highlights from Ecolab’s 2024 Year in Water include:
- Water conservation: Ecolab helped customers conserve more than 226 billion gallons of water, equivalent to the annual drinking water needs of more than 781 million people. By 2030, Ecolab aims to help conserve 300 billion gallons of water annually, equivalent to the drinking water needs of 1 billion people.
- Business growth: Ecolab continued to grow its Global Water business through the acquisition of Barclay Water Management, helping enhance its water safety and digital monitoring solutions.
- AI-driven solutions: Ecolab collaborated with Digital Realty to deploy an AI-driven water conservation solution in 35 of Digital Realty’s U.S. data centers, aiming to improve water use efficiency and reduce environmental impact.
- Water treatment partnerships: Nalco Water, Ecolab's water and process management business, partnered with Danieli to enhance industrial water treatment for the metals industry, aiming to improve production processes, reduce carbon and water footprints, and lower costs.
- Consumer engagement: Ecolab elevated awareness of the importance of water during New York Climate Week with its “Every Drop Counts” exhibit in Bryant Park. It also continued its annual Ecolab Watermark™ Study, which reports on the state of water stewardship around the world.
- Leading certifications: Ecolab continued pursuing Alliance for Water Stewardship (AWS) certification, bringing its total count of AWS-certified facilities to 12. Ecolab also earned the Water Stewardship Verified (WAVE) certification for its leading water stewardship efforts.
- Innovative funding: Ecolab participated in a $10 million funding round led by Emerald Technology Ventures to accelerate the global deployment of an innovative PFAS treatment technology, the LEEF System®.
- Convener of water action: As cofounder of the Water Resilience Coalition (WRC), an industry-driven, CEO-led initiative under the UN Global Compact, Ecolab is committed to addressing the global water crisis. Over the past year, Ecolab helped the WRC make significant strides towards its 2030 roadmap:
- Investing in Safe Water and Sanitation: Along with Microsoft, Starbucks, Xylem, Reckitt, Gap Inc. and others, Ecolab contributed to the Water & Climate Resilience Fund by WaterEquity. This innovative impact fund has raised more than $100 million, aiming to provide safe water or sanitation access to 15 million people across Africa, Asia and Latin America.
- Championing California's Water Resilience: As Basin Champion for drought-stricken California, Ecolab convened the second annual forum of the California Water Resilience Initiative (CWRI). This private sector initiative accelerates coordinated, collective action to achieve a water-resilient future for California, aligning with public sector goals.
- Recognition: Ecolab received public accolades for sustainability, climate and water leadership from CDP, JUST Capital, the Dow Jones and Barron's, among others.
- Smart Water Navigator: Ecolab continued to offer its informative digital tool to help businesses understand the full value of water in their operations and achieve water goals.
Ecolab’s mission to protect vital resources and deliver business growth is more critical now than ever in the age of AI. By prioritizing smart water management, Ecolab is helping businesses perform while building a more resilient and positive future. Learn more at: https://www.ecolab.com/expertise-and-innovation/water.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. www.ecolab.com
Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.
(ECL-C).
1Bloomberg Law, “AI Computing on Pace to Consume More Energy Than India, Arm Says,” April 2024. https://news.bloomberglaw.com/artificial-intelligence/ai-computing-on-pace-to-consume-more-energy-than-india-arm-says.
2Ecolab analysis of data from Lei, N., & Masanet, E. (2022) and Goldman Sachs (2024).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250321820071/en/
Contacts
Kim Del Alcazar
+1-612-483-3698
MediaRelations@Ecolab.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press Release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press Release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom